2X1 Stock Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ABIVAX Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.78 |
| 52 Week High | €19.50 |
| 52 Week Low | €7.96 |
| Beta | 1.46 |
| 1 Month Change | 1.03% |
| 3 Month Change | 30.00% |
| 1 Year Change | -1.57% |
| 3 Year Change | -38.21% |
| 5 Year Change | 42.65% |
| Change since IPO | -2.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2X1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -1.6% | -19.9% | 0.9% |
Return vs Industry: 2X1 exceeded the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: 2X1 underperformed the German Market which returned 0.9% over the past year.
Price Volatility
| 2X1 volatility | |
|---|---|
| 2X1 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2X1's share price has been volatile over the past 3 months.
Volatility Over Time: 2X1's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 61 | Marc M. de Garidel | www.abivax.com |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme Fundamentals Summary
| 2X1 fundamental statistics | |
|---|---|
| Market cap | €890.91m |
| Earnings (TTM) | -€147.74m |
| Revenue (TTM) | €4.49m |
198.3x
P/S Ratio-6.0x
P/E RatioIs 2X1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2X1 income statement (TTM) | |
|---|---|
| Revenue | €4.49m |
| Cost of Revenue | €0 |
| Gross Profit | €4.49m |
| Other Expenses | €152.23m |
| Earnings | -€147.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 09, 2024
| Earnings per share (EPS) | -2.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,288.23% |
| Debt/Equity Ratio | 37.7% |
How did 2X1 perform over the long term?
See historical performance and comparison